The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology.

Trial Profile

The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2012

At a glance

  • Drugs Atorvastatin (Primary) ; Sitagliptin (Primary)
  • Indications Alzheimer's disease; Atrial fibrillation; Cardiovascular disorders; Diabetic foot ulcer; Heart failure; Hypercholesterolaemia; Hyperlipoproteinaemia type II; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Low HDL cholesterol; Neurological disorders; Systemic lupus erythematosus; Type 2 diabetes mellitus
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 19 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top